<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681457</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452A2109</org_study_id>
    <nct_id>NCT03681457</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor (LJN452) in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of hepatic impairment on the
      systemic exposure of tropifexor and to evaluate the safety of tropifexor in subjects with
      hepatic impairment. The results of this study will support treatment and dosing decisions for
      patients with varying degrees of hepatic impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">September 25, 2019</completion_date>
  <primary_completion_date type="Actual">September 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The maximum (peak) observed drug concentration after single dose administration (mass x volume-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Time to reach the maximum (peak) plasma drug concentration after single dose administration (time)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The area under the concentration-time curve from time zero to the time of the last quantifiable concentration sampling time (mass x time x volume-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The area under the concentration-time curve from time zero to infinity (mass x time x volume-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The apparent total body clearance of the drug from plasma (volume x time-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The apparent volume of distribution during the terminal phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fu</measure>
    <time_frame>Day 1</time_frame>
    <description>Fraction of analyte unbound calculated in-vitro</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The maximum (peak) observed plasma drug concentration after single dose administration (Cmax) of unbound drug (mass x time x volume-1), calculated as Cmax*fu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The area under the concentration-time curve from time zero to the last quantifiable concentration sampling time of unbound drug (mass x time x volume-1), calculated as AUClast*fu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The area under the concentration-time curve from time zero to infinity of unbound drug (mass x time x volume-1), calculated as AUCinf*fu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,u</measure>
    <time_frame>Day 1</time_frame>
    <description>The apparent total body clearance of drug from the plasma of unbound drug (volume x time-1), calculated as CL/F/fu</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Group 1 - Normal Hepatic Function</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal hepatic function - Control - control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild hepatic impairment - Child-Pugh A (Score 5-6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment - Child-Pugh B (Score 7-9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe hepatic impairment - Child-Pugh C (score 10-15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LJN452</intervention_name>
    <description>Dose A single dose</description>
    <arm_group_label>Group 1 - Normal Hepatic Function</arm_group_label>
    <arm_group_label>Group 2 - Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 3 - Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 4 - Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All subjects:

        Inclusions Criteria:

          -  Subjects must weight at least 50 kg, with a BMI within the range of 18 to 38 kg/m2

          -  Must be willing to remain in the clinical research unit as required by the protocol

        Exclusion Criteria:

          -  Use of other study drugs at the time of enrollment, or within 5 half-lives of
             enrollment, or within 30 days, whichever is longer; or longer if required by local
             regulations

          -  History of hypersensitivity to the study treatment or to drugs of similar chemical
             classes

          -  Pregnant or nursing women

          -  Women of child-bearing potential

        Healthy Volunteers:

        Inclusion Criteria:

        - In good health as determined by past medical history, physical examination, ECG,
        laboratory tests, and urinalysis at Screening.

        Exclusion Criteria:

          -  Liver disease or liver injury

          -  Chronic infection with Hepatitis B or Hepatitis C

          -  History or presence of impaired renal function

        Hepatically Impaired Subjects:

        Inclusion Criteria:

        - Hepatic impairment as defined by the Child-Pugh classification for severity of liver
        disease

        Exclusion Criteria:

          -  Severe complications of liver disease within the preceding 3 months

          -  Emergency room visit or hospitalization due to liver disease within the preceding 3
             months for mildly and moderately hepatically impaired subjects, and within the
             preceding 1 month for severely hepatically impaired subjects

          -  Subject has received liver transplant at any time in the past and is on
             immunosuppressant therapy

          -  Acute Hepatitis B or Hepatitis C infection

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LJN452, tropifexor, PK, safety, healthy subjects, hepatically impaired</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

